These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 9143195)

  • 1. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytokines and septic shock. New perspectives on its treatment].
    Zamora Madaria E
    An Med Interna; 1993 Dec; 10(12):573-5. PubMed ID: 8049320
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monoclonal antibodies in the treatment of septic shock].
    Trilla A; Alonso P
    Med Clin (Barc); 1992 Dec; 99(20):778-80. PubMed ID: 1460950
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monoclonal antibodies in the treatment of sepsis and septic shock].
    Torrabadella de Reynoso P; Salgado Remigio A; Peracaula Picart R
    Med Clin (Barc); 1992 Dec; 99(20):784-92. PubMed ID: 1460952
    [No Abstract]   [Full Text] [Related]  

  • 9. Current prospects for the treatment of clinical sepsis.
    Suffredini AF
    Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The application of molecular biology to anti-endotoxin therapies].
    Someya T; Sasaki K; Hirata K
    Nihon Geka Gakkai Zasshi; 2003 Jul; 104(7):523-6. PubMed ID: 12884777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 12. Sepsis and SIRS.
    Bone RC
    Nephrol Dial Transplant; 1994; 9 Suppl 4():99-103. PubMed ID: 7800276
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapies directed against endotoxin--has the time come?
    Quezado ZM; Hoffman WD
    West J Med; 1993 Apr; 158(4):424-5. PubMed ID: 8317138
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunotherapy of sepsis and septic shock].
    Ivanović D; Gjurasin M; Gasparović V; Radonić R; Kvarantan M; Merkler M
    Lijec Vjesn; 1995 Jun; 117 Suppl 2():8-11. PubMed ID: 8649167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Septomonab (Centoxin) in the treatment of gram-negative septicemia].
    Fomsgaard A
    Ugeskr Laeger; 1993 Apr; 155(14):1066-71. PubMed ID: 8497944
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, pathophysiology and clinical presentation of gram-negative sepsis.
    Hazinski MF; Iberti TJ; MacIntyre NR; Parker MM; Tribett D; Prion S; Chmel H
    Am J Crit Care; 1993 May; 2(3):224-35; quiz 236-7. PubMed ID: 8364674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiendotoxin therapies for septic shock.
    Corriveau CC; Danner RL
    Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.